Skip to main content
GWGovwatch
CongressBillsCommitteesPresidentMoneyPulseMisconductElectionsMap
Donate

Weekly accountability digest

One email a week with new votes, moving bills, and misconduct updates. No spam.

GW

Govwatch. Public data about Congress, in one place, in plain English.

Built with public data. Not affiliated with the U.S. government.

Explore

  • Officials
  • Legislation
  • Committees
  • Congress Pulse
  • Trending Topics
  • Bipartisan Leaderboard
  • Weekly Digest
  • Misconduct
  • Predictions

Learn

  • How Congress Works
  • How a Bill Becomes Law
  • Campaign Finance 101
  • Glossary

Tools

  • My Representatives
  • Compare Members
  • Bill Watchlist
  • Search
  • District Map
  • Follow the Money
  • Watch Live

Site

  • About
  • Contact
  • Corrections
  • Privacy Policy
  • Terms of Service

Data Sources

Congress.gov API v3
Bills, members, votes
GovInfo API
Floor speeches, reports, bill text
Federal Election Commission (FEC)
Campaign finance
VoteView (UCLA)
Ideology scores (DW-NOMINATE)
GovTrack.us
Misconduct data (CC0)
U.S. Census Bureau
District demographics

Data Last Updated

Bills & Votes: 4 hours ago
Support This Project

This site is free. Donations help cover hosting, API fees, and keeping the data fresh.

All data is sourced from official government APIs and public records. This site is for informational purposes only.

© 2026 Govwatch

HRES1509Referred to Committee

Recognizing the extraordinary resilience and courage of children and families fighting neuroblastoma and supports the incredible effort of clinicians and researchers working to address this disease and expressing support for September 3, 2026, to be designated as "Neuroblastoma Awareness Day".

Share:
Introduced
In Committee
3
Passed One Chamber
4
Passed Both
5
Signed into Law
119th
Congress
2026-09-03
Introduced
1
Cosponsors
HRES
ⓘ
Type

Sponsor

Judy Chu
Judy Chu
Democrat · CA · Representative
Votes with party: 98.5% (652 recorded votes)

Full profile: /officials/C001080

Source: Congress.gov · FEC

Cosponsors (1)

Members who have signed on to support this bill since introduction. Source: Congress.gov.

  • Mike Kelly (R-PA-16)Original· 2026-09-03

Latest Action

The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →

Referred to the House Committee on Oversight and Government Reform.

2026-09-03

Source: Congress.gov

Committee Activity

Currently in

  • House Committee on Oversight and Government ReformReferred To · 2026-09-03

Plain-English Summary

Plain-English summary pending. Introduced on 2026-09-03. Check back soon — summaries are generated as bills progress through Congress.

Subjects

Health

Full Bill Text

Verbatim text published on Congress.gov via GovInfo. Use Cmd+F / Ctrl+F to search within this excerpt.

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H. Res. 1509 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. RES. 1509 Recognizing the extraordinary resilience and courage of children and families fighting neuroblastoma and supports the incredible effort of clinicians and researchers working to address this disease and expressing support for September 3, 2026, to be designated as ``Neuroblastoma Awareness Day''. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES September 3, 2026 Ms. Chu (for herself and Mr. Kelly of Pennsylvania) submitted the following resolution; which was referred to the Committee on Oversight and Government Reform _______________________________________________________________________ RESOLUTION Recognizing the extraordinary resilience and courage of children and families fighting neuroblastoma and supports the incredible effort of clinicians and researchers working to address this disease and expressing support for September 3, 2026, to be designated as ``Neuroblastoma Awareness Day''. Whereas neuroblastoma is the most common cancer in infants and the most common extracranial solid tumor in childhood; Whereas there are approximately 600 to 800 new cases of neuroblastoma diagnosed each year in the United States; Whereas neuroblastoma accounts for about 8 to 10 percent of all childhood cancers and approximately 15 percent of childhood cancer deaths; Whereas approximately 90 percent of neuroblastoma cases are diagnosed before 5 years of age, with many cases occurring during infancy; Whereas symptoms are often nonspecific, which can delay diagnosis and treatment; Whereas neuroblastoma accounts for a disproportionate share of pediatric cancer deaths relative to its incidence; Whereas high-risk neuroblastoma remains one of the most difficult pediatric cancers to treat successfully; Whereas the estimated 5-year survival rate for children with high-risk neuroblastoma is approximately 63 percent; Whereas treatment for high-risk neuroblastoma typically requires intensive multimodal therapy, including chemotherapy, surgery, radiation therapy, stem cell transplant, and immunotherapy; Whereas survivors may experience significant lifelong health complications, including hearing loss, organ failure, and subsequent malignancies; Whereas children with neuroblastoma often require prolonged treatment and repeated hospitalizations; Whereas anti-GD2 immunotherapy has improved outcomes for children with high-risk neuroblastoma; Whereas emerging therapies, including CAR-T cell treatments targeting tumor antigens such as B7-H3, are under active investigation for relapsed disease; Whereas childhood cancers, including neuroblastoma, historically receive significantly less research funding compared to adulthood cancers; Whereas children with high-risk or relapsed neuroblastoma continue to face limited effective treatment options and a high risk of relapse, highlighting the need for continued research and therapeutic development; Whereas increased awareness can support earlier diagnosis, improve outcomes, and help drive investment in research and treatment advancements for pediatric cancers; Whereas September is recognized as Childhood Cancer Awareness Month in the United States; and Whereas the House of Representatives supports designating September 3, 2026, as ``Neuroblastoma Awareness Day'': Now, therefore, be it Resolved, That the House of Representatives supports the designation of a ``Neuroblastoma Awareness Day'' to provide a dedicated opportunity to recognize the extraordinary resilience and courage of children and families fighting this disease and support the incredible effort of clinicians and researchers working to address this disease. <all>
Open clean-text viewRead on Congress.gov →

Related legislation

Bills by the same sponsor or covering overlapping subjects.

  • HR10045Protect American Values Act
    Referred to Committee · 2026-08-06
  • HR9699Drug Deal Disclosure Act
    Referred to Committee · 2026-07-15
  • HR9400American Rescuers of the Holocaust Congressional Gold Medal Act of 2026
    Referred to Committee · 2026-06-23
  • HR9024Harry Lew and Danny Chen Military Justice Reform Act
    Referred to Committee · 2026-05-26